Last week, Intellia Therapeutics announced that it had received clearance to begin a clinical trial for NTLA-2002, an in vivo CRISPR therapy candidate...

Poseida Therapeutics' unique approach to gene editing and delivery addresses some of the major obstacles faced within cell and gene therapy...

CRISPR-based blood cell therapies are advancing through clinical trials, with promising results stacking up for certain rare genetic diseases and some...

New research on X-linked Agammaglobulinemia has led to the development of a potential gene therapy cure for this disease - or as Dr David Gray...

Last weekend, Intellia Therapeutics and Regeneron announced first-ever clinical data that support the safety and efficacy of in vivo CRISPR genome...

In this week’s update, we present a CRISPR-based therapy for sickle cell disease (SCD) that has moved from the investigational new drug (IND) stage...

β-Thalassemia is caused in part by a mutated β-globin gene, so researchers developed a way to replace the entire mutated gene with a healthy version...

In this brief roundup, we look at what's going on in the CRISPR Medicine field for Leber congenital amaurosis, an inherited group of rare retinal...